MedDeviceGuide — IVD & Medical Device Knowledge Base
EU Implementing Regulation 2026/977: Uniform Notified Body Requirements Under MDR and IVDR
A complete guide to Commission Implementing Regulation (EU) 2026/977, published May 4, 2026, which sets uniform quality management and procedural requirements for Notified Bodies conducting conformity assessments under the MDR and IVDR. Covers maximum timelines, clock-stop rules, quotation transparency, re-certification procedures, and what manufacturers need to know.
IVDR Class C Transition Deadline: What IVD Manufacturers Must Do Before May 26, 2026
A practical survival guide for IVD manufacturers facing the May 26, 2026 IVDR Class C transition deadline. Covers who must apply to a Notified Body, the September 2026 agreement deadline, conditions for extended market access through 2028, common pitfalls, and a step-by-step action plan.
MDCG 2026 Updates: Classification Guidance, EMDN Codes, and Borderline Manual Changes Explained
A practical guide to the April 2026 MDCG updates affecting every EU medical device and IVD manufacturer. Covers MDCG 2021-24 Rev.1 classification guidance changes, EMDN v3/2026 code updates (MDCG 2026-1, 2026-2, 2026-3, MDCG 2021-12 Rev.2), the Borderline and Classification Manual Version 5, and what manufacturers must do to stay compliant.
Auto-Injector Critical-Task Matrix for Human Factors Validation: How to Identify, Document, and Test Every Safety-Critical Use Step
Practical guide to building the critical-task matrix for auto-injector and pen-injector human factors validation — task identification from URRA, needle shield removal, site selection, dose confirmation, hold time, misfire recovery, training decay, disposal, use-error root cause analysis, and FDA/IEC 62366 evidence expectations.
EPA Ethylene Oxide Emissions Regulations for Medical Device Sterilization: 2026 Proposed Rollback, Compliance, and Supply Chain Impact
How the EPA's 2026 proposed rollback of ethylene oxide emissions standards affects medical device manufacturers, sterilization facilities, and supply chains — the 2024 rule, proposed changes, compliance timelines, and alternative sterilization strategies.
eSTAR Additional Information Response Playbook: How to Answer FDA Deficiency Letters Inside the eSTAR Workflow
Step-by-step playbook for responding to FDA Additional Information requests in eSTAR 510(k) and De Novo submissions — response table format, file naming, version control, section mapping, RTA vs substantive deficiencies, and traceability to original submission sections.
EU AI Act + MDR Single Evidence Matrix: How to Build One Combined Technical File Without Duplicating Work
A field-by-field evidence matrix mapping MDR Annex II/III technical documentation, ISO 14971 risk management, PMS/PMCF, cybersecurity, data governance, human oversight, and QMS records to EU AI Act high-risk obligations — for manufacturers who must comply with both frameworks simultaneously.
EUDAMED Bulk Upload Validation Error Playbook: Diagnose and Fix XML/XSD Rejections Before the May 2026 Deadline
A systematic playbook for diagnosing and resolving EUDAMED bulk upload validation errors — covering XSD schema failures, Basic UDI-DI/UDI-DI mismatches, EMDN code issues, certificate linkage errors, DTX error codes, NB confirmation bottlenecks, and a pre-upload validation checklist.
FDA AI-Enabled Device Predicate Mining Method: How to Identify, Evaluate, and Defend Your Predicate for 510(k) and De Novo
A methodical approach to mining FDA's AI-enabled device list and 510(k) database for predicate devices — covering technological characteristic extraction, public summary limitations, weak predicate argument avoidance, and a complete predicate evaluation matrix.
FDA ASCA Test Report Acceptance Package: How to Build a Bulletproof Evidence Package for 510(k) and De Novo Submissions
Step-by-step guide to building the ASCA evidence package for 510(k) and De Novo submissions — ASCA Summary Test Report, declaration of conformity, lab accreditation status check, scope matching, withdrawn/suspended lab risk, FDA questions, and submission rescue strategies.
FDA Cybersecurity Unresolved Anomalies Table: How to Document Vulnerabilities and Residual Risk in Premarketing Submissions
How to build the Unresolved Software Anomalies table for FDA premarket cybersecurity submissions — CVSS scoring, exploitability assessment, clinical impact analysis, compensating controls, SBOM linkage, VEX status, labeling language, release criteria, and common reviewer objections.
FDA Third Party Review Program Due-Diligence Checklist: How to Decide Whether 3P510k Is Right for Your 510(k) Submission
Practical due-diligence checklist for evaluating the FDA Third Party Review (3P510k) Program — product-code eligibility verification, Accredited Person selection, conflict-of-interest screening, eSTAR compatibility, FDA final-determination risk, timeline and cost tradeoffs, and when to avoid third-party review.
GB PMSR/PSUR Dual-Report Architecture: How to Structure Post-Market Surveillance Reports for Devices Sold in Both EU and Great Britain
Step-by-step guide to building a dual PMSR/PSUR reporting architecture that satisfies both EU MDR/IVDR and Great Britain SI 2024/1368 requirements — data-period alignment, GB-specific content, MHRA standardized format, FSCA linkage, trend reporting, record retention, and responsible-owner mapping.
Home-Use IVD Invalid-Result Workflow: How to Design, Document, and Monitor Invalid Results for Consumer Diagnostics
Operational guide to the invalid-result workflow for home-use and self-test IVDs — covering invalid rate targets, lay-user error coding, repeat-test instructions, IFU comprehension, customer support scripts, specimen collection errors, adverse event handling, and postmarket trending.
IEC 62304 Edition 2 (2026): Software Process Rigor Levels, AI/ML Provisions, and What Changes for Medical Device Manufacturers
A comprehensive guide to IEC 62304 Edition 2 — the 2026 update replacing safety classes A/B/C with rigor levels, expanding scope to all health software, adding AI/ML lifecycle requirements, integrating cybersecurity, and practical compliance timelines for medical device manufacturers.
IVDR Companion Diagnostic Consultation File: How to Prepare the NB–EMA/National Authority Interface Package
How to prepare the consultation file for IVDR companion diagnostics — notified body submission to EMA or national medicinal product authorities, package contents, analytical and clinical performance evidence, drug label alignment, timing, deficiency risks, and the Team-NB V2 decision flowchart for significant changes.
MDR Article 88 Trend Reporting: How to Set Statistical Thresholds, Detect Adverse Trends, and Build a Defensible Reporting Workflow
A practical guide to implementing MDR Article 88 trend reporting — covering denominator selection, expected frequency calculation, statistical significance testing, severity escalation, complaint coding, CAPA linkage, PSUR/PMSR integration, and the MDCG 2025 draft Q&A requirements.
MDUFA VI: FDA Medical Device User Fee Reauthorization 2027–2032 — What Manufacturers Need to Know
A comprehensive guide to MDUFA VI — the 2027-2032 FDA medical device user fee agreement covering CDRH staffing restoration, America-First fee restructuring, real-world evidence provisions, fee projections, and practical preparation strategies for device manufacturers.
NGS Bioinformatics Pipeline Change-Control File: How to Document, Revalidate, and Audit Every Pipeline Update
Practical guide to change control for NGS bioinformatics pipelines in IVD devices — covering variant caller updates, reference database changes, threshold modifications, wet-lab/software interface validation, IEC 62304 documentation, revalidation triggers, and postmarket records.
PCCP Drift Monitoring Protocol for AI Imaging Devices: Dataset Shift Detection, Performance Thresholds, and Retraining Triggers
How to design and implement a drift monitoring protocol for AI-enabled imaging devices under FDA PCCP — dataset shift, scanner drift, demographic drift, performance thresholds, monitoring cadence, retraining triggers, labeling changes, and when FDA submission is still required.